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Abstract   Lipids are crucial components of the human body. They are the major components of 
cell membranes and govern important biological pathways. Due to their fundamental roles in 
key biological processes, synthetic lipid analogs have been invaluable for applications 
including elucidation of lipid function, molecular labeling, drug delivery and cell engineering. 
In chapter one of this thesis, we describe the development of synthetic lipids to characterize 
multivalent protein−lipid binding interactions. . Toward this end, we present progress in the 
design and synthesis of deuterated lipid analogs and their application to characterize the 
changes in lipid clustering driven by protein−lipid binding interactions using neutron 
scattering techniques. Additionally, in Chapter two we report progress towards the design 
and synthesis of stimuli-responsive lipids for the purpose of targeted drug delivery. Here we 
discuss the design and synthesis of a Zn2+ responsive lipid to fulfill the purpose of targeting 
Zn2+ overdosed disease cells to enhance liposomal drug-delivery applications.  
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Chapter 1: Synthesis of deuterated analogs of key signaling 
lipids for neutron scattering studies to investigate the dynamics 
of biological activities in membranes 
 
1.1 Overview 
Multivalent protein-lipid binding interactions occur frequently on the cellular level and 
govern vital biological processes related to health. However, despite such importance, 
multivalent protein-lipid binding interactions are poorly understood due to the complexity 
of membrane environments. Studies of such interactions have been conducted using 
synthesized probes in simple models, but the probes introduced can influence the 
physicochemical properties of the membrane. Small-angle neutron scattering (SANS) has 
recently been established as an efficient tool for the investigation of membrane surfaces to 
study processes such as domain formation. 
The initial phase (Aim 1) of this project is to synthesize deuterated lipid analogs of 
phosphatidylinositol 4, 5-bisphospate (PI(4,5)P2) and phosphatidylserine (PS). These 
analogs bear deuterated acyl chains that enable differentiation from normal lipids by SANS 
in low concentration. Thus, bilayer vesicle systems can be created by combining deuterated 
lipid analogs with protonated phosphatidylcholine (PC) lipids to act as simplified model 
systems for the plasma membrane (PM). The next phase (Aim 2) of the project will be to 
study multivalent protein-lipid bindings using SANS. During this phase, the interactions of 
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multivalent proteins profilin-1 with deuterated PI(4,5)P2and annexin A5 and CA HIV capsid 
protein with deuterated PS will be examined to understand the changes in mobility and 
clustering of PI(4,5)P2and PS caused by multivalent protein binding. The final phase of the 
project (Aim 3) will be to characterize binding via the modification of acyl chain length, 
saturation, size of the vesicle, concentration of analogs, etc. Figure 1 depicts the different 
phases of the project and Figure 2 shows the structure of the normal lipids and their 
deuterated analogs. The focus of this thesis is the synthesis of the deuterated analogs 
required for SANS studies. Future SANS work will be conducted at Oak Ridge National 
Laboratory (ORNL).Cooperation with ORNL offers access to the state of the art Spallation 
Neutron Source for obtaining high quality data pertaining to changes in membrane structure 
driven by protein binding. 
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Figure 1 General scheme of the project. Phase 1: the synthesis of deuterated lipid analogs; Phase 2: Protein-lipid binding studies using Spallation Neutron Source; Phase 3: Computer simulations that aid in interpreting the experimental data. 
3 
 
 
O O
Phosphatidylcholine (PC) Phosphatidylserine (PS) Phosphatidylinositol-(4,5)-
biphosphate (PI(4,5)P2)
O
O
O
O
O O OO
O O O O
n n n nn n
P
-
O
O
O
(H3C)3N
P
-
O
O
O
O
O
NH3
O
P O
-
O OH
OPO32
--2O3PO
A.
B.
O O
O
O
O
O
CD2CD2
D3C D3C
O O OO
O O
CD2 CD2
D3C D3C
O O
CD2
D3C
CD2
D3Cn n
n nn n
P
-
O
O
O
(H3C)3N
P
-
O
O
O
O
O
NH3
O
P O
-
O OH
OPO32
--2O3PO
Deuterated PC Deuterated PS Deuterated PI(4, 5)P2
HO
HO OH
OH
O
O
 
Figure 2 The lipids used in the experiment. A. Structures of natural lipids PC, PS and PI(4,5)P2; B. Deuterated analogs of PC, PS and PI(4, 5)P2. The deuterated parts are the acyl tails attached to the diol structure of the head group.  
1.2 Background 
1.2.1 Introduction of PIPns and PS 
Phosphatidylionsitol polyphosphates (PIPns) are a group of seven isomeric lipids that 
control vital biological pathways that relate to signal transduction on the cell surface as well 
as the regulation of membrane traffic, the cytoskeleton, nuclear events and the permeability 
and transportation of membranes1-4. Among them, PI(4,5)P2,which is enriched in the plasma 
membrane, is a crucial factor in cell trafficking, signaling and prolongation4,5. PI(4,5)P2 is the 
precursor for PI(3,4,5)P3, a vital signaling lipid involved in signal transduction and 
phagocytosis, catalyzed by phosphatidylinositol 3-kinases(PI3Ks). PI(4,5)P2 also serves as a 
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precursor for secondary messengers such as diaclyglycerol (DAG) and D-myo-inositol 
(1,4,5)-triphosphate (InsP3). Phospholipase C (PLC) catalyzes the hydrolysis of PI(4,5)P2 to 
release DAG and InsP31-4. InsP3stimulates calcium release by binding to the high affinity 
inositol triphosphate receptors (InsP3Rs) in the endoplasmic reticulum (ER)6-8. DAG binds to 
protein kinase C (PKC) and stimulates cell growth. Through the binding of small GTPases 
such as Cdc42, PI(4,5)P2 can bind N-WASP to trigger conformational changes that lead to the 
binding and activation of ARP 2/3 complex, which promotes actin polymerization6,7,9. 
PI(4,5)P2 also assists actin filament elongation at the actin filament tip by advancing the 
dissociation of the capping proteins including gelsolin and CapZ7. Binding with profilin 
facilities the formation of dissociable actin-monomers-profilin complexes that enhance 
addition of G-actin7,9. As one of the major PIPns that governs the cellular activities on the 
plasma membrane, the study of PI(4,5)P2is essential in understanding a variety of biological 
processes that occur on the membrane surface. 
PS is an anionic lipid first discovered in brain lipid extracts by Folch10-12in the 1940s. It 
contains a serine head group phosphorylated at the sn-3 position of the lipid body, which 
causes it to attract cations to the cell membrane.13 PS is a key component in attraction and 
activation of various proteins bound to the cell membrane. For example, activated blood 
platelets expose PS on the outer surface of the membrane.14 The exposed lipid binds and 
activates coagulation enzymes including annexin A5, PKCα, PKCβ, coagulation factor V, and 
prothrombin.13,14 The majority of PS is restricted to the cytosolic domains on the inner cell 
membranes held by the enzyme flippase.15 However, during the stages of apoptosis and 
necrosis13,15, PS flips to the outer membrane of the cell due to the inactivity of flippase.16 PS 
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also serves as a mediator for virus entry into the cell.13, 17 Studies by Chen18, 19 have revealed 
that soluble bovine protein S (GAS 6) can bridge the viroin envelope PS of the vaccinia virus 
to the TAM receptor tyrosine kinase on target cells. Works done by Callahan and Soares20 
indicated that PS influences HIV entry, but the detailed mechanism is poorly understood. The 
uses of SANS could provide a beneficial method for resolving the structure and dynamics of 
multivalent protein-lipid binding interaction of PS and PI(4,5)P2. 
1.2.2 Protein-lipid interactions 
 The plasma membrane (PM) and interior organelle membrane of cells consists of 
proteins, sterols and various lipids that possess non-random lateral organizations and 
exhibit complex biological activities.21 Proteins and corresponding lipids interact with each 
other in numerous ways to perturb the dynamics and functions of the PM. Protein-lipid 
binding interactions are key phenomenona that monitor biological processes including cell 
signaling, prolongation, apoptosis, transportation, etc.22 The protein-lipid binding can be 
classified as monovalent or multivalent. Multivalent protein-lipid binding is of interest due to 
its abundance and importance in cellular membranes and since it is a poorly characterized 
phenomenon. One example is profilin-1, which is an actin-binding protein that regulates 
actin polymerization in response to extracellular signals. Instead of regulating actin 
polymerization, profilin-1 has been found to bind PI(4,5)P2 in a 1:7 ratio with high affinity. 
Profilin-1 competes with PLC in the binding of PI(4,5)P223, inhibiting the hydrolysis of 
PI(4,5)P2 to release secondary messengers DAG and InsP3 which interrupts the 
phosphoinositide signaling pathway. Cations such as Ca2+are involved in some multivalent 
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protein-lipid binding interactions. Annexin A5 binds to PS on the membrane of blood 
platelets to activate the cognition process.13,14 The binding of annexin A5 to PS is dependent 
on the Ca2+level surrounding it. Multivalency also plays major roles in virus recognition and 
insertion into the cell. Human immunodeficiency virus-1 (HIV-1) displays the surface 
envelope protein gp 120 and membrane transfer protein gp 41 that are involved in the 
recognition and insertion of mRNA into the host cells.24 Gp 120 and gp 41 are suggested to 
be the main influencing factors of viroin tropism. However, the PS of the lipid membrane of 
the virus can also direct the recognition in the situation of low affinity binding site for gp 120. 
The CA capsid protein of HIV interacts with PS during the process of virus 
replication17,18,19,24. This interaction is crucial in the formation of and release of new viral 
bodies. CA consists of multiple domains for PS19, but none of the interactions are well 
understood. Because such processes occur in the inner leaflet of the PM, the characterization 
of the structure and dynamics of binding interactions of profilin-1, annexin A5 and CA to the 
corresponding lipids could boost the understanding of important biological processes and 
general rules of multivalency. 
 One of the biggest challenges in studying multivalent protein-lipid interactions are 
multivalent carbohydrate-protein interactions. Due to the weak interactions that single 
carbohydrates and lipids form with proteins, multivalency is beneficial for enhancing the 
affinity and specificity of proteins for their target ligands.22 The spacing of hydroxyl groups 
plays an important role in molecular recognition.22 However, such structures are difficult to 
observe and conformational changes after the binding process are difficult to characterize. 
Despite these obstacles, research on carbohydrate multivalency has progressed well. This 
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encourages the study of multivalency in protein-lipid binding, which is still poorly 
understood.  
1.2.3 Analysis of lipids using SANS 
Application of SANS to the study of lipids has emerged as a promising method to 
characterize the micro domains of lipid membranes.21 This method utilizes the high 
sensitivity of neutron in the differentiation of hydrogen from its isotope, deuterium. SANS 
was developed from the early attempts of using X-ray scattering to characterize 
nanometer-scale heterogeneity of membrane surfaces.21 Early studies have proven the 
sensitivity of small-angle X-ray scatterings to separate physical domains, but this technique 
lacks contrast resolving the composition of the membrane. In order to further analyze the 
domain separation of the PM, neutron scattering was introduced to monitor the lipids 
bearing deuterium. The high sensitivity of neutrons towards deuterium requires only 
deuterated acyl chains to contrast the targeted lipid. Thus, the deuterated lipids are tag-free 
lipid probes essential for neutron scattering.21 Generally, contrast tags are required to 
identify the biological processes that occur in the PM. However, some tags can influence the 
physicochemical properties of lipid analogs, which will introduce undesirable artifacts to the 
data that is obtained. Deuterated lipid analogs require only replacement of hydrogen with 
deuterium to generate high resolution scattering curves without changing the lipid 
properties.  
 The most developed application of SANS in the study of lipid membranes lies in the 
characterization of raft domains on binary or ternary membrane systems. The basic strategy 
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is to create ideal vesicle models containing deuterated lipid analogs. Such systems have 
previously been developed mostly by employing deuterated PC analogs. Anghel25, in 2007, 
presented a mathematic treatment that models the scattering of a single round domain that 
arises on the hypothesis that smaller domains onunilamellar vesicles (ULVs) will coalesce 
into a single large domain to minimize the boundary energy cost. Then, the scattering 
intensity is governed by vesicle size, domain size, area fraction and composition. This model 
is used to calculate its scattering, which is then compared to the experiment data to examine 
the membrane lateral heterogeneity. The Monte Carlo method21 is used to model vesicles 
with multiple domains and more complex morphologies where single round domain model 
fails. This method requires construction of a variety of models of different domains and 
morphologies and then assigns random spots of the system, from which the theoretical 
scattering plots are calculated and compared to the experimental data. The best-matched 
morphology is the model that showed the least differences between its scattering and that of 
the experimental SANS data. The biggest disadvantage of the modeling method is the amount 
of time spent on the construction of plausible models. Thus, model-free analysis methods are 
being developed.  
Pencer and coworker26, in 2006, proposed that the Porod invariant method can detect 
the lateral membrane heterogeneity in ULV suspensions. The notion of this method is that 
the Porod invariant can be decomposed into three terms corresponding to the scattering 
length density (SLD) contrast between the average vesicle composition and the solvent; the 
radial SLD fluctuations that result from the different SLDs of the lipid heads and acyl chains; 
and the lateral SLD fluctuations resulting from domains of different acyl chain composition. 
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The first term is eliminated by matching the SLD of the vesicle to the SLD of the solvent and 
the third term is enhanced by the deuteration of acyl chains in lipid analogs. The second is 
usually suppressed to decrease its contribution to the additional scattering intensity. The 
power law scattering model27 is applied to multilamellar vesicles whose average SLD 
matches that of the solvent. In this case, the scattering intensity follows a power law, 𝐼𝐼(𝑞𝑞) ∝
𝑞𝑞−𝐷𝐷. The exponent D characterizes the packing and geometry of the membrane system. D 
characterizes the bulk structure when it is between 0 to 3 and it represents the surface 
structure when it is between 3 and 6. The forward scattering method, proposed by Knoll28, 
modulates the solvent SLD to interrogate the membrane heterogeneities in MLV. This method, 
however, only applies to small, uniform and uncorrelated lipid domains.  
 Neutron and X-ray reflectivity have also been applied for the study of binding 
interactions on the membrane surface. Recent work of neutron/x-ray studies of cholera toxin 
(CTAB5) interactions with lipid mono-layers has exhibited the potential of neutrons.29 CTAB5 
contains the subunits AB5 and CTB5 (B subunit), from which the B subunit contributes to the 
binding of cell-surface receptor ganglioside GM1. In order to characterize the binding 
interaction of CTAB5 and GM1 on the cell surface, the membrane system of 
2-dipalmitoyl-sn-glycero-3-phosphoethanol-amine: galactosyglucosylceramide (DPPE: GM1) 
was used. The acyl chains of DPPE were deuterated in the neutron study and hydrogenated 
in the X-ray study. Neutron and X-ray reflectivity profiles, which contains information of 
depth profiles of the interrogated regions, are measured of the bulk DPPE/GM1 monolayer, 
the monolayer with CTB5 and the monolayer of CTAB5 on a D2O sub phase. The analysis of 
the reflectivity profiles was conducted by fitting real-space depth profile models to the 
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measured reflectivity curves. Both neutron and X-ray data showed alignment of the B5 
subunit binding to the monolayer while the A subunit of CTAB5was facing a way. Density 
increases of the monolayer were observed by contrasting the reflectivity data of the 
monolayer and the toxin bonded monolayer. X-ray grazing incidence diffraction (GID) 
experiments confirmed the density change of the monolayer after the enzymatic activation of 
CTAB5or CTB5. The percentage of CTB5 coverage to the monolayer was calculated by 
measuring the hydrogen-deuterium exchange ratio after the toxin binding. Neutron and 
X-ray beam damage experiments were also conducted and demonstrated that neutrons are 
less destructive to the membrane system and bond protein than X-rays. 
 Prior studies of rafts25,26,27,28 and cholera toxin binding29 using neutron scattering 
validates the idea that SANS can be a powerful tool to characterize the structure and 
dynamics of multivalent protein binding. 
1.3 Experiment Methods and Studies 
1.3.1 Synthesis of deuterated PI(4,5)P2and PS analogs 
 In order to synthesize the deuterated PI(4,5)P2 analog, the molecule was divided into 
two separate parts30, the phosphorylated myo-inositol head group and the deuterated lipid 
tails. Then with the help of phosphoramidite chemistry, the two parts of the analog will be 
coupled together to form the desired molecule. An essential part of the synthesis is that the 
stereochemistry and regiochemistry of the head group must be controlled. 
The method developed by Bruzik31 was applied to accomplish phosphorylation at the 
inositol 4 and 5 positions. To connect the molecule to the lipid tail, various protection steps 
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must be performed. As shown in Figure 3, myo-inositol was protected by activated 
dimethoxyl D-camphor, which protects the inositol 2 and 3 positions. Isomers of molecule 2 
will influence the stereochemistry of the later compound. It was purified through 
recrystallization in MeOH solution31,32,33 (with 1% triethylamine to prevent 
rearrangement).The inositol 1 position, which will connect to the lipid chain, was then 
protected with one equivalent of tert-butyl(chloro)diphenylsilane (TBDPSCl) to produce 3. 
Following that, two molar equivalents of benzoyl chloride (BzCl) were introduced slowly to 
react with the inositol 4 and 5 positions, directed by the sterics of the bulky TBDPS group 
and yielding 4. After the protection of inositol 4 and 5 position, D-camphor was removed 
with trifluoroacetic acid (TFA), which resulted in three hydroxyl groups on the inositol 2, 3 
and 6 positions of product 5. These groups were protected by benzyl chloromethyl ether 
(BOMCl) to prevent intervention in later reactions. The hydroxyl groups at the inositol 4 and 
5 positions were then released using MeONa/MeOH to generate product 6. 
N,N-bis(1-methylether)-bisphenylmethyl-phosphoramidite acid ester was used to 
phosphorylate the inositol 4 and 5 positions to 7. The hydroxyl on the inositol 1 position was 
released via deprotection of the TBDPS group using tetra-N-butylammonium fluoride (TBAF) 
to produce 8. This hydroxyl group will be used to link the head group to the glycerolipid 
scaffold.       
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Figure 3 Synthetic route to protected phosphorylated myo-inositol head group.  The synthesis of the deuterated lipid tail began with commercially available 
(4S)-2,2-dimethyl-1,3-dioxolane-4-methanol. The hydroxyl group was protected using 
4-methoxybenzylchloride (PMBCl)34 and then the acetonide protecting group was removed 
in the acidic conditions of TsOH/MeOH or acetic acid31. Deuterated lipid chains were then 
attached by dicyclohexylcarbodiimide(DCC) and 
N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate(HBTU). The 
cleavage of the PMB protection group was done through 
oxidationwith2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). Glycerolipid 13, shown in 
Figure 4, can be coupled not only to the PI(4,5)P2 head group but also the other phosphate 
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lipids head groups to produce different lipids such as PS for future studies. 
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Figure 4 Synthesis route to deuterated lipid tail (glycerolipid). Deuterium tags are in the two acyl chains, the length of which can be controlled to study the influence of chain length on the fluidity of the membrane. 
 After obtaining molecules 13 and 8, the deuterated PI(4, 5)P2 analog can be finished as 
shown in Figure 5 Molecule 8 is coupled with a phosphoramidite reagent first, then 
molecule 13 is added with extra H-tetrazole. Finally, meta-chloroperoxybenzoic acid 
(m-CPBA) will be used to oxidize the phosphotriester group. The purified compound will 
then be deprotected by reduction in a hydrogen atmosphere catalyzed by Pd/C, resulting in 
deuterated PI(4, 5)P2 analog. However, this reaction did not result in promising compound 
14 after multiple trials using different solvent systems including dry benzene, dry toluene, 
dry chloroform, dry THF and dry benzene/THF. It is possible that the protection groups of 8 
are too bulky, thus blocking the coupling reaction due to sterics. 
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Figure 5 Attempt final steps of synthesis of deuterated PI(4,5)P2. 
  Deuterated L-serine analogs can be synthesized using methods similar to the prior 
deuterated PI(4, 5)P2 synthesis35. As shown in Figure 6, the starting material Boc-L-serine 
was treated with the same chemical conditions, which resulted in boc-protected PS precursor. 
Deprotection of this compound with AcOH, hydrogen atmosphere and Pd/C catalyst resulted 
in deuterated serine analog. The reaction did not proceed smoothly as expected after trial of 
various solvent system of dry benzene, dry toluene, dry chloroform, dry THF and dry 
benzene/THF.  
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Figure 6 Final coupling steps in the synthesis of deuterated PS. 
 In order to make compound 14, alternative protection groups were studied to reduce 
the steric interaction of protecting group with the phosphoramidite reagent. Specifically, the 
BOM protecting group was replaced by MOM protection as a match smaller protecting group 
than the big benzene, shown on Figure 7. 
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Figure 7 Synthesis of MOM-protected intermediate 21. 
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 After producing compound 21, various tests were conducted using two different kinds 
of phosphoramidite reagents to obtain products 22 and 23. After trying all the solvent 
combinations mentioned above and switching 1H-tetrazole to 4, 5-dicyanotetrazin, the 
desired products did not appear.  
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Figure 8 Attempted synthesis of compound 22 and 23. 
 
In order to make compound 17, compound 16 was reacted first with a 1:1 ratio of 
phosphoramidite reagent to form compound 24, which was immediately quenched with 
saturated sodium bicarbonate and separated via silica gel column and quenched with 1-2% 
triethyl amine solvent system. Afterwards the compound 24 needs to be dried by vacuum to 
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remove remaining triethylamine prior to proceeding to the next reaction. The compound 
rapidly oxidized after 2 days under high vacuum condition (wrapped with tin foil) and lasts 
for a week in fridge. 
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Figure 9 Synthesis of compound 17. 
 
 Another effort to successfully obtain compound 15 involved changing the steric bulk of 
the R group in the phosphoramidite reagent. Thus, methanol and dry ethanol were distilled 
and freeze dried prior to the reaction.  
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 Deuterated phosphatidic acid analog 27 was also pursued by using compound 13 to 
produce26, followed by deprotection via Pd/C (10%) in AcOH solution and then column 
chromatography with chloroform to 65/35/4 chloroform/methanol/water or 50/35/5 ratio 
of chloroform/methanol/AcOH.   
 
O O
(CD2)n
D3C
(CD2)n
D3C
O O
13
HO
O O
(CD2)n
D3C
(CD2)n
D3C
O O
26
O
PBnO
OBn
O
H2, Pd/C (10%)
AcOH
O O
(CD2)n
D3C
(CD2)n
D3C
O O
27
O
PHO
OH
O
1. 1H-tetrazole      
CH2Cl2
2. m-CPBA
78%
P
BnO OBn
N
 
Figure 11 Synthesis of compound 27. 
1.3.2 SANS experiments  
 After the synthesis, deuterated PS and PI(4,5)P2 analogs mixed with bulk lipids 
including PC (PC is most abundant lipid in eukaryotic membranes) will be treated in 
traditional conditions37for forming vesicles, which are shown on Figure 12. Vesicles 
composed of d-PI(4, 5)P2/PC and d-PS/PC will be made for SANS studies. The initial ratios of 
d-PI(4, 5)P2/PC (d-PS/PC) of the vesicles are designed to be 1:19, 1:9, 3:17, 1:4, 1:3, 3:7, 2:3, 
1:1 and pure PC (control). The composition of the vesicles can be changed by controlling the 
weight of deuterated analog and PC used in formation of the vesicle. Each set of vesicles will 
then be suspended in solution of H2O/D2O with different concentrations of 5%, 10%, 20%, 
30%, 40%, 50%, 60%, 70%, 80%, 90% and 100% of deuterated water.  
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The scattering of the above vesicles solutions will be monitored by SANS, first to obtain 
base-line signals for the experiment. In order to eliminate the scattering of the vesicle, 
scattering data will be compared to find H2O/D2O combinations that minimize the scattering 
of the vesicles. During this process, the radius and average scattering density of the vesicles 
can be calculated and confirmed via scattering intensity data.  
Then d-PI(4, 5)P2/PC vesicles will be incubated with profilin-1and d-PS/PC vesicles 
incubated with annexin A5 and CA HIV capsid protein. The control set of pure PC vesicles 
will also be incubated with each target proteins. Proteins, regarding their sizes and complex 
structures, exhibit strong scattering signals. Thus, control of pure target proteins will be run 
with protein only solution samples. For the binding of annexin A5 to deuterated PS analog, 
Ca2+ is needed to promote the binding process. The influence of the presence of the Ca2+ 
cations will be carefully examined to prevent unwanted scattering intensity. After the 
binding process is complete, SANS will be performed. Data plots of scattering intensity 
profiles will then be collected and analyzed.  
 
Lipid Vesicle with Deuterated
Analog
PI(4,5)P2
 
will be denser on the 
Profilin binding side
=deuterated PI(4,5)P2
 or deuterated PS
=PC
Protein
Protein
Protein=profilin-1 (PI(4,5)P2), annexin A5 (PS),               
CA HIV capsid protein (PS)  
Figure 12 The multivalent protein-lipid experimental scheme. Lipid vesicles contain non-deuterated PC and deuterated lipid analogs of PI(4, 5)P2 or PS. The binding proteins are profilin-1, which will interacts with PI(4,5)P2, and annexin A5 and CA HIV capsid protein which will bind to PS. Both SANS signals of before and after the binding will be collected.  
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1.3.2.1 Preparation of Lipid Vesicles 
 Phospholipids contain a hydrophilic head group and two hydrophobic lipid tails.33, 34The 
structure in nature thermodynamically drives the self-assembly of phospholipids to form 
bilayer membranes in aqueous conditions. Thus, lipid vesicles can be generated by hydration 
of dry lipid films. However, such liposomes created are usually large multilamellar vesicles 
(LMV) with disordered structures.35 Most vesicles will envelope multiple lipid vesicles 
within. Sonication and extrusion are two techniques that organize and control the radii and 
structure of bilayer lipid vesicles.36, 37With the known radii and physical properties of the 
lipid, the concentration, surface area, and lipid tags concentration can be estimated via 
mathematics. 
1.3.2.2 Preparation of dry lipid film/cake 
 Liposome films/cakes with evenly scattered deuterated-tags and PC will be generated 
by the evaporation of lipid solutions. The combination of 9:1 chloroform to methanol is often 
applied to dissolve the lipids. However, the solvent system can be modified to benefit 
solubility and versatility.36, 37 After evaporation of the solution using drying N2 gas or 
rotavapor, a thin lipid film will be formed. The film is usually placed on a high vacuum 
afterwards to remove all organic solvent.   
 The concentration of the deuterated tags depends on the ratio of deu-PS/deu-PI(4,5)P2 
to PC dissolved in organic solvent. This can be achieved by controlling the mass of lipids used. 
In order to conduct SANS experiments, liposome films containing 0%, 5%, 10%, 15%, 20%, 
25%, 35%, 40%, 45%, 50% deuterated tags will be created by evaporation of 7:1, 9:1 and 
21 
 
15:1 chloroform and methanol solutions. Additional d-DAG and PC dry films will be created 
to study on the clustering of DAGs by Ca2+on vesicle surfaces.  
1.3.2.3 Hydration of lipid film/cake 
 Lipid films will self-assemble to LMVs when treated in aqueous environment. 
Non-charged lipids tend to form vesicles easier, while the charged phospholipids might 
require treatment with a small amount of salt to prevent clustering.36 LMVs can be 
significantly reformed into bilayer vesicles by constantly cooling and heating the sample 
between acetone dry ice bath and hot water bath. The reformed bilayer vesicles exhibit a 
broad radii range that must be concentrated. 36, 37 
 The SANS experiment requires different contrast of aqueous phase to vesicles to have 
clear scattering signals. Thus, H2O: D2O ratio of 1:9, 1:4, 3:7, 2:3, 1:1, H2O only and D2O only 
aqueous solvents will be applied to hydrolyze the films.  
1.3.2.4 Sizing of the vesicle suspension 
 In order to conduct SANS experiments, the sizes (radii) of the liposomes must be 
controlled for estimation of vesicle concentration, concentration of deuterated tags per 
vesicle, vesicle surface area and the number of deuterated tags on the liposome surface. 
These data, along with the information regarding the properties of deuterated-tags and PC 
are required for modeling and interpretation of the SANS data. 
 Techniques such as sonication and extrusion36, 37 will be applied to control the size of 
the vesicles. Sonication utilizes sonic waves to break the vesicles and allow vesicle fractions 
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to evenly reform when the temperature decreases. Extrusion technique controls the size of 
the vesicles by forcing them to pass through nano-sized pores. The technique of extrusion 
outweighs sonication in forming vesicles of unified size, and the size of the vesicles can be 
easily controlled using filter with different pores, which can benefit the study of the influence 
of vesicle size on the protein-lipid binding and experimental contrast. But, passing the 
vesicles through pores might result in the loss of lipids, which might influence the accuracy 
of the data analysis. Sonication on the other hand, tends to create small unilamellar vesicles 
(SUV) of 5-50 nm. However, the condition of sonication is harsh due to the melting of 
phospholipids for the destruction of LMV and formation of SUV. Therefore, the extrusion 
method will be used to form vesicles of designed size. 
 To calculate the number of lipids and concentration of deuterated tags requires the 
information of the lipids, such as chain length (to average them), area of the head group and 
distance of the neighboring lipids. With the known vesicle radii, the ratio of PC and 
deuterated tags, the properties of vesicles can be calculated. One big problem is the 
concentration of the liposomes. This can be calculated if the volume of the sample, vesicle 
radii and distances of each vesicles are known. Transmission electron microscopy (TEM) can 
be used to image the vesicle suspension and measure the average distance of each vesicles. 
1.3.2.5 Protein-lipid Binding Experiment 
 With the prepared d-PS/d-PI(4,5)P2and PC vesicle suspension, SANS experiments will 
be conducted to explore the morphology of the vesicles during protein-lipid binding.38 The 
structure of proteins Annexin V, HIV-1 CA and Profilin-1 can be identified using X-ray 
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crystography. However, lipids exhibit long flexible tails that will not form crystalline 
structures required for X-ray analysis. Shortening the chain length and modification of 
functional groups can result in crystalline structures that can be detected by X-ray 
crystallography. However, natural lipids possess long hydrophobic chains, thus the structure 
characterized does not fully represent the morphology of protein-lipid binding in the actual 
cell surface. Hydrogen and deuterium exhibit different scattering powers as characterized by 
their neutron scattering length densities (SLD), which makes neutron scattering a powerful 
tool to characterize proton rich biological systems. The biggest challenge in understanding 
protein-lipid interactions is the characterization of long lipid tails on the surface of protein 
after the binding interaction. Therefore, by labeling the binding lipids, deuterated PS and 
PI(4,5)P2, the morphology of the lipids after binding to the protein can be characterized.   
 In order to gain scattering signals that monitor the behavior of the proteins, the contrast 
of vesicles to the solvent system is examined first with prepared samples of different 
concentration, vesicle radii, tag to PC ratio, and solvent with different ratio of H2O and D2O. In 
poorly scattered samples, the scattering contrast between the aqueous solvent and vesicles 
is small, which allows the scattering of the binding proteins to be followed. 
 Samples with only one variable will be gathered as one group to investigate the 
influence of that variable to the scattering signals. Samples containing PC vesicles or just 
solvent will be used as control of the experiment. 
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1.3.2.6 SANS experiment without protein-binding interaction 
 The neutron scattering technique will not visualize the sample by feeding back images 
of the bond protein and lipids. Thus, analysis of the data requires modeling of the scattering 
curves with differentiable contrast39. Before the binding experiment starts, scattering signals 
of each samples will be gathered. These signals will be the base line for the interpretation of 
SANS data. 
 For the samples of d-PS/PC, scattering data of bulk samples and Ca2+ treated 
suspensions will be collected as well. Ca2+ plays vital role in the clustering of PS and PS 
binding ability, marking its importance in the interaction of PS to Annexin V protein and 
HIV-1 CA protein.  
1.3.2.7 SANS experiment of protein-binding interaction 
 After gathering the data of 2.1, Annexin V and CA will be treated with samples 
containing a suspension of d-PS and PC. Samples without Ca2+ will also be investigated to 
gather further information about binding without the cation bridge. Profilin-1 will bind to 
samples containing d-PI(4,5)P2 and PC vesicles. Collected data will be matched with the 
paired data gathered from 2.1 for analysis. 
1.3.2.8 Raft formation of deuterated DAG with Ca2+ 
 Binding sites of the protein and lipids on plasma membrane might be located in areas 
called ‘rafts’. Experiments of raft formation using high-melting point lipids and low-melting 
point lipids have been investigated.5 However, rafts also contain lipids attractive to 
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surrounding cations. Binding of cations could influence the binding affinity of the lipids or 
trigger certain biological pathways. Therefore, with existing DAGs, raft formation caused by 
the clustering of lipids induced by cations is also interesting and promising. The procedure is 
similar to that of 2.1-2.2.  
1.3.3 Neutron Reflectometry Experiments 
 Neutron reflectometry, similar to SANS, monitors the reflection of the neutron beam 
from the sample surface to characterize the biological properties.40 Unlike preparation of 
vesicle suspensions in SANS experiments, neutron reflectometry experiments will be 
conducted on lipid bilayer or monolayer sheet on supporting materials. During the 
experiment, the incident angle will be increased and the reflective intensity will be gathered 
to characterize the interacted system. The patterns of changes of reflectivity with the 
increase of the incident angle or wavelength are influenced by the depth profile of the 
samples, including the ‘roughness’ of the surface and the thickness and number of layers. A 
decreasing fluctuant signals will usually be viewed, which contains the structural 
information of the thin film. Neutron reflectometry can also  be used to determine the 
scattering length density profile perpendicular to the smooth flat interface.41 In this 
experiment, the reflected neutron beam can be analyzed to provide information of a lipid 
layer, protein-lipid bond layer and different peptide portions of the protein.40, 41 Through 
measuring the signal of the lipid head group region, the density profile of deuterated tags 
before and after binding can be observed. 
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1.3.3.1 Preparation of Lipid Layer 
 In order to created lipid monolayers or bilayers for the reflectometry experiment, a 
sheet of hydrophobic glass will be dipped into a solvent mixture of d-PS/d-PI(4,5)P2 with PC. 
In this way the hydrophobic lipid tails will attach to the glass surface forming a stable 
monolayer even when treated in water.42 Bilayers can be created by coating the head group 
of lipids on the supporting sheet and coating the sample lipid layer on top of it.43 However, in 
the case of lipid monolayers, the interaction of acyl chain to the supporting material could 
make the lipid too rigid to displace and interact with the protein. Another proposed way to 
generate the lipid monolayer is to place the lipids on the middle of the chloroform phase and 
aqueous phase. This might be accomplished by adding certain percentage of H2O to D2O 
slowly to the organic solvent of the dissolved lipids. In order to conduct the experiment 
monolayers of deuterated tags and PC in different ratio will be created.   
1.3.3.2 Detection of the Protein-lipid Interaction 
 The reflectivity of the sample monolayers with 1) nothing; 2) targeted protein and 3) 
cations (Ca2+) will be measured.44 By fitting the data of a model depth profile with the 
reflectivity curve, scattering length density depth profiles of the samples will be obtained. 
Plots of scattering length density depth profile will be created to elucidate the density 
changes of the deuterated tags before and after binding to the protein. The sequence of how 
the protein is attached to the lipids can also be observed by analyzing the reflectivity data.  
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1.3.4 Data analysis and improvement 
 Models are required for the interpretation of the scattering data. Identified binding 
regions may provide information regarding the density change of the liposome, which might 
be caused by the accumulation of deuterated analogs to the binding site. However, an 
understanding of these processes cannot be achieved without the help of models. In the 
work of cholera toxin, the box model used was based on the already known crystal structure 
of the toxic proteins. The binding of cholera toxin to the lipid monolayer also creates 
crystalline like regions that are easier to characterize. The crystal structure of 31 profilin-1, 
annexin A5 and CA HIV capsid protein are already known.38-40 Multivalency of our 
protein-lipid binding may create rigid regions that simplify the mathematical representation. 
The modeling will then mostly focus on the morphology of vesicles after the binding 
interaction. The easiest model for the experiment is the single round domain to which only 
one protein is attached and the majority of the analogs accumulate around it. The opposite 
region can be assumed as a pure PC entity. In most cases, the Monte Carlo method will be 
applied since multiple binding domains might exist for the target proteins and the vesicle 
may exhibit complex morphology after binding. My assumption for this scenario is that the 
binding sites will distribute evenly on the vesicle surface to reduce the energy associated to 
it. The surface of the vesicle might be in shapes of ellipsoid or ball with convex regions 
associate with protein binding sites. However, we will seek out collaborators to assist with 
such computer modeling. Feedback from the model fit will provide geometrical and 
morphological information vital to the study of multivalency of protein-lipid binding 
interactions. Improvements will be made mainly to change the protein/d-analog ratio to 
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construct a system similar to single round domain model, which will simplify the amount of 
modeling requires. 
1.3.5 Experimental Insight 
 One unique property of SANS is the huge contrast of hydrogen and deuterium. 
Deuteration of lipid acyl chains will enhance the scattering signals of these moieties, which 
enables the characterization of the lipid tails that cannot be accomplished by other methods. 
In addition, matching the scattering contrast of bulk PC and the aqueous solvent will 
highlight the signals of protein and its bonded lipids. In this way characterization of lipid 
morphology, especially the long hydrophobic tails, during protein-lipid binding interaction 
will be possible, which will boost the understanding of the molecular role of lipids, especially 
the physiochemical changes brought by lipids, in protein-lipid interactions. The experiments 
will also advance the knowledge of lipids in various biological pathways. For example, the 
role of lipids, especially physical movements of lipids, during endocytosis and exocytosis. 
The benefits and influences of proteins via binding with lipids in Golgi body can also be 
examined using the models and methods developed from this project. 
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Chapter 2: Development of metal-ion responsive liposomes for 
drug delivery. 
 
2.1 Overview 
Zinc metal ions play vital roles in human biological activities. It has been shown that the 
fluctuation of unbounded Zn2+ in blood vessels and cell junctions causes various diseases 
such as neuron damage, cell unregulated growth and even some specific tumor growth62-71. 
In this chapter we describe efforts to develop a Zn2+ triggered liposome formulation to 
respond to increases in Zn2+ concentrations associated with disease onset to achieve the goal 
of precise cargo delivery to diseased cells. Toward this goal, this project will be divided into 
the following steps. The first aim is the design and synthesis of a Zn2+ responsive lipid based 
on tris-picolylamine (TPA) ligands. The second aim of the project is the formation of various 
liposomes delivery systems using zinc-responsive lipids and other common lipids such as PC. 
Next, release studies will be conducted with hydrophobic dyes such as nile red encapsulated 
within liposomes to analyze release driven by Zn2+treatment.Liposomes will also be tested 
for release of water-soluble dyes entrapped within the aqueous core. The third aim of the 
project involves cell delivery studies using fluorescence microscopy. 
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2.2 Background 
2.2.1 Liposome drug delivery system 
Liposomes are nano-delivery devices that have exhibited promising clinical results and 
tremendous applications. Lipids contains hydrophobic and hydrophilic ends, which enable 
them to selfassemble into multilamiller vesicles or unilamiller vesicles that can encapsulate 
pharmaceutical drugs within their aqueous cavities or hydrophobic membrane bilayers 
depending on the polarity of the drugf45, 46, 47. Liposomes can also possess charged or neutral 
membrane surfaces for specific delivery purposes46,47. The broad surface area of liposome 
enables a variety of modifications to make the cargo target specific, and increase durability45, 
46, 47. Unlike other nano-delivery systems, liposomes are composed mostly of lipids 
commonly found within the human body, and thus liposome delivery systems possess far 
less cell toxicity than other nano-delivery systems, which has resulted in various approvals of 
clinical trials by the Food and Drug Administration (FDA)46. Due to the above advantages, 
liposome drug-delivery system shows great promise for advancing drug delivery 
applications. 
Like various materials such as alloys, glasses, polymers etc, liposome can be engineered 
into vesicles with controlled size, composition and membrane layers. Various methods have 
been developed to influence the size, lamellarity and encapsulation efficiency of the 
liposome vesicles. The first and commonly used method for the preparation of liposome is 
the Bangham method46, 48, which is also called thin lipid film hydration method. This method 
is commonly used and is a simple procedure. The desired components are mixed in ratio 
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inside vial or round bottom flask and dissolved in organic solvent. After various dry freezing 
procedures, a thin lipid film will form, which then will selfassemble into liposomes after 
introducing it into an aqueous environment. Vigorous shaking while rehydrating results in 
multilamellar liposome vesicles and gentle shaking results in giant unilamellar liposome 
vesicles49. Sonication of samples results in more homogenous vesicles but the heat effect of 
ultrasound can damage heat sensitive materials46. To select more homogenous sized vesicles, 
dilution devices and size-exclusion columns can be utilized to select the size of the liposome 
vesicles45. However, this method possesses possible drawbacks of low encapsulation potency 
and mixture of multilamellar and unilamellar vesicles47. More advanced methods of micro 
hydrodynamic focusing of microfluidic technology46, 50, the supercritical reverse phase 
evaporation method46, 51, 52 and the spray drying methods46, 53 have been applied to make 
more controllable liposome vesicles with high loading potentials. For certain diameters of 
micro fluid channels, the perpendicular intersection of channels with organic solvent and 
aqueous buffer creates the lamellar flow of liposome vesicles46. The size, ratio, loading 
potency and lamellarity of the liposome is controlled by the concentration and flow speed 
ratios of the organic solution and the aqueous buffer50. Co-axial flow method in glass 
capillaries is a different variant of the same method. The supercritical reverse phase 
evaporation method, which was introduced in 200152, is a technique that produces large 
unilamellar liposomes. This method uses supercritical carbon dioxide to dissolve the lipids 
and other moieties and then pump them to chamber that contains an aqueous drug at a 
desired concentration. By depressuring and temperature control, perfect unilamellar 
liposomes with homogenous size can be formed46, 51, 52. The advantages of this method are 
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the high encapsulation efficiency and avoidance of the drug-organic solvent contact47, 53. The 
spray drying method is commonly used in the pharmaceutical industry for 
large-scaleproduction53.  
The common activation of liposome cargo can be categorized into passive delivery and 
active trigger-based delivery46.The passive delivery system utilizes the unregulated tissue 
activities to deliver the drug to the targeted cell47. For example, the unregulated intake of the 
tumor cells and its huge size can result in higher possibility of cargo intake or release46, 47, 
due to changes in the physical and chemical environment of the area. This method requires 
the long circulation of liposome within the blood vessel to achieve high delivery rate46. Thus, 
stable liposome composition and membrane surface modification (PEGylating) is a main 
focus to achieve the delivery goal47. Unlike passive delivery, active triggered-based delivery 
system is more target specific and release controllable. The most common example is to 
insert pH-sensitive moieties into the outer liposome membrane46, 47. Upon entering the 
acidic environment of the tumor cell, the triggered physical and chemical change of the 
liposome by the targeting ligands results in drug release and delivery46. Targeting ligands 
can be varied according to the acceptor moieties chosen. Inner cellular activation can also 
reduce the multidrug resistance of the targeted cell45. Due to its versatility, target specific 
and controllable activation of the active-triggered delivery system, the liposome drug 
delivery system provides a platform to accomplish the project. 
 
33 
 
2.2.2 Importance of zinc ions in human body 
Even though the human body contains low concentrations of zinc ions, regulation and 
balance of this ion is critical for human health. One of the key features of zinc in the human 
body is its role in binding enzymes or coenzymes. It has been estimated that at least 10% of 
human proteins potentially bind zinc, which indicates its crucial biological activities54, 55, 56. 
Zn containing enzymes, such as carbonic anhydrase56, 57, 58 and carboxypeptide56, 59 play 
important roles in carbon dioxide regulation and protein digestion. Carbonic anhydrase57, 
which regulates carbon dioxide by reversible conversion to bicarbonate59. This conversion 
enables the release of carbon dioxide through the lungs when the pH is near 760. Another key 
zinc binding motif is the zinc finger, which regulates the transcription and replication of 
DNA56, 61. 
Zinc is also located inside the tongue and human glands that regulate taste and fluid 
secretion56. The transportation of zinc ions is conducted by albumin and transferrine56 and 
the concentration of zinc in blood vessel should stay static to regulate biological activities56. 
Despite the various examples of bound zinc discussed above, a small minor portion of zinc 
exists in an unbounded free state inside blood vessels and cell junctions. This small 
percentage of Zn2+, even in nano molar concentrations, is involved in the regulation of 
transcription, cell growth, reproduction, nervous system and immune responses. Free zinc is 
tightly regulated since high concentrations of zinc are toxic, while deprivation of zinc can 
lead to cell damage and unregulated biological processes.  
One of the most fascinating series of zinc-related diseases involve overdoses of free zinc 
surrounding human tissues. The brain, respiratory tract, gastro intestinal tract, prostate and 
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immune system all express disease symptoms due to overdoses of zinc ions62. High doses of 
unbound zinc in prostate tissue can lead to cancerous behavior, while the surrounding 
environments of prostate cells are normally lower in zinc concentration62, 63, 64. Zinc is 
involved in leukocyte signal transduction, which will influence the behavior of T cell 
functions by serving as a co-factor for the thymic hormone thymulin65, 66. Free zinc ions also 
act as neuron modulators, for which an overdose can cause lethargy and focal neuronal 
deficits67, 68, 69. Expulsion of high Zn2+ions on the surface of skin and respiratory tract causes 
pain and vomiting62. Furthermore, free Zn2+ ions in the human body also influence the 
copper ion concentrations62 since excess Zn2+ has been found to cause copper deficiency, 
which leads to various diseases, such as hypocupremia69, impaired iron mobilization72, 
anemia73, leukopenia74, neutropenia75, decreased superoxide dismutase76 (SOD) (particularly 
erythrocyte SOD (ESOD)), ceruloplasmin as well as cytochrome-c oxidase77. 
Since zinc ion overdose leads to serious diseases, liposomal release driven by zinc ion 
binding presents a promising avenue for targeted drug release and delivery to cells 
possessing an increased abundance of zinc.  
2.2.3 Zn2+ responsive ligands 
To develop a zinc trigger-based delivery of drugs to targeted cells in response to excess 
Zn2+ concentrations, we set out to engineer a zinc-binding domain into a lipid structure. The 
ideal binding ligand would possess a dissociation constant (Kd) that enables the binding of 
micro molar Zn2+ concentrations while not responding to normal blood Zn2+ concentrations78, 
79, 80in order to be activated under excess Zn2+ environments. Lippard and co-workers78, 80 
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have developed various pyridine based Zn2+ sensors that exhibit beneficial binding 
properties. For example, ZP1, ZP2 and ZP3 contain di(2-picolyl)amine (DPA) ligands that 
chelate Zn2+ at median concentrations around neuron cells to monitor the change in Zn2+ 
concentration during cellular activities. These are designed as fluorescence sensors that 
exhibit enhanced fluorescence signals when Zn2+ concentration increases. According to all 
the data78, 79, 80 combined from Lippards work, the Kd of these series of compounds is around 
0.5-5nM, which makes these compounds suitable for detecting Zn2+ concentration in 
neuronal cell junctions. 
Another important aspect of Zn2+ chelators are their selectivity towards other metal 
ions such as Na+, K+, Ca2+and Fe2+, which are typical competitors that are found within the 
human body. In one of Lippard’s work, his team analyzed the selectivity and pH fitness of the 
ZP1 fluorescence sensor80 by testing ZP1 with Na+, K+, Ca2+, Cu2+, Fe2+ and Co in a buffer that 
mimics normal blood pH. The sensor did show increased fluorescence with different 
concentrations of the above ions, while after the addition of a 50 micromolar ZnCl2 solution 
fluorescence increased significantly. This provided inspiration for using TPA ligands as Zn2+ 
selective chelators for our Zn-triggered liposomes.  
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Figure 13 Lippard’s ZP1, ZP2 and ZP3 series of Zinc chelating flurophores78. 
 
2.2.4 Key feature for promising delivery system 
The most important feature for the success of this project is the synthesis of Zn2+ 
chelating ligands sensitive to minor Zn2+ concentration differences within cell environments 
and their adaptation into a liposome system with normal blood plasma stability and cargo 
release potential. The delivery system should be able to bind to excess Zn2+andrespond to 
Zn2+ overload. It is also important to develop a corresponding liposome system with high 
encapsulation efficiency, homogenous unilamellar vesicle and minimal cell toxicity.    
2.3 Liposome design and study methods 
2.3.1 Zn2+ binding liposome 
The proposed Zn2+ responsive lipid is shown below in Figure 14. The tris-pyridine 
amine system contains three amide linkages by which 12 carbon chains are attached to serve 
as membrane anchors. It is expected that conformational changes that occur after chelating 
to Zn2+will destabilize liposomes into which the trigger is incorporated and thereby cause 
the release of contents. While our initial design is shown in Figure 14, this lipid can be 
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modified to optimize release. For example, different lipid chains with varying lengths and 
unsaturations could be explored. This can be done to tune the physical properties such as 
melting point, entanglement and size of opened pores. Halides or other functional groups 
can be attached to the pyridine rings or one of the pyridine rings can be changed to influence 
the binding potential of the lipid as well as modifying chemical and physical properties. 
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Figure 14 Structure of the proposed Zn2+responsive lipid. 
 
2.3.2 Membrane encapsulation studies 
After the preparation of the lipid probe, liposomes composed of phosphatidylcholine 
(PC), the zinc trigger and the dye Nile red will be prepared. Nile red is encapsulated within 
the membrane to mimic hydrophobic cargo delivery. Various compositions of liposomes 
containing different lipid additives will be evaluated. The particle sizes of each liposome will 
be measured by dynamic light scattering (DLS) to ensure the formation of stable liposomes 
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of the appropriate size and study the effects of zinc binding. Each liposome solution will be 
titrated with increasing Zn2+ concentration and fluorescence will be measured. It has been 
shown that Nile red release from liposomes leads to a decrease in fluorescence due to 
precipitation from solution, shown in Figure 15. This assay will be used to measure the 
extent of dye release from liposomes and the concentration of zinc required for release. 
Controlled samples will be run using PC liposomes lacking the zinc trigger to determine 
background release. This experiment can be conducted by including other bulk lipids such as 
cholesterol to determine the effect on release in both the study and control samples. We will 
also test release with other metal ions present to probe for selectivity.  
 
Zn2+
Nile Red
Zn2+
 
responsive lipid
Figure 15 Release of Nile red from liposomes caused by zinc binding. 
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2.2.3 Pores encapsulation studies 
With insights learned from the above studies, we will next study the release of 
hydrophilic agents such as rhodamine B dye and doxorubicin encapsulated inside the 
liposome aqueous interior. Similar steps will be taken to plot release curves resulting from 
titration with Zn2+. After selection of best liposome composition, non-cargo release study 
will be conducted with normal human cells or human liver cells to study the cellular toxicity 
of the delivery-system. Encapsulation efficiencies can be calculated using the detergent 
triton X to stimulate complete release from the liposome.  
 
Zn2+
Dox, Rhodamine B
Zn2+
 
responsive lipid
Figure 16 Release of hydrophilic contents from liposomes driven by zinc binding. 
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2.4 Experiment details and discussion 
Different synthetic routes have been explored for the synthesis of our proposed zinc 
trigger. One initial route is shown in Figure 17 in which the starting material 2, 
4-dicarboxylpyridine (28) was chelated to copper to form 29. According to literature81, 
treatment of 29 with thionyl chloride (SOCl2) can be used to produce the corresponding acid 
chloride that can be reacted with amine to form 30. However, different solvents including dry 
benzene and dry DMF were tested and the result was not successful, and thus an alternative 
method was chosen. 
 
(II)Cu
N
COOH
N
COOH
O
O
O
-
O
-
(II)Cu
N
C
N
C
O
O
O
-
O
-
O
Cl
O
Cl
1000C reflux
(II)Cu
N
C
N
C
O
O
O
-
O
-
NH
NH
H2N 11
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Figure 17 Initial synthetic pathway pursued toward the synthesis of zinc trigger. 
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In order to selectively reduce the carboxylic group on the 2-position of compound 28, 
esterification was performed to produce compound 32 (Figure 18). Selective reduction of 
32 was then used to synthesize compound 33, as previously described in the literature.82 
 
N COOH
COOH
N COOCH2CH3
COOCH2CH3
N
COOCH2CH3
OH
Dry ethanol
TsOH, reflux
CaCl2, NaBH4
Dry EtOH, -10-00C
28 32
33
Figure 18 Synthesis of compound 33. 
 
Following the synthesis of compound 33, we next set out to produce amine 38 (Figure 
19). This was performed by converting the hydroxyl group of 33 to leaving groups including 
the chloride of 34 or bromide of 35. Both of these were converted to azide 37, which was 
then reduced to 38. Formation of iodide 36 was unsuccessful. 
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Figure 19 Synthesis of pyridine building block 38. 
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After obtaining compound 38, this was reacted with 2-3 equivalents of halides 34 and 
35 in dry dichloromethane with the addition of potential templates Li2CO3, Na2CO3, K2CO3 
and Cs2CO3. Due to the radius and surface area of the template, Li2CO3 resulted in a higher 
yield of 39. The esters of 39 were then hydrolyzed to produce compound 40 under basic 
conditions and then the solution was acidified to precipitate 40 as a white solid. Afterwards, 
various amide coupling reagents including HBTU, EDCI, DCC and SOCl2were tested in solvent 
systems of DMF, Chloroform, benzene, toluene, benzene/THF and dichloromethane, and 
resulted in formation of product 41 as judged by TLC. Compound 40 was also ionized and 
tested with HBTU, but no result occurred. It is possible that solubility differences between 
41 and alkylamines were problematic. Thus, we modified the synthesis to first make 
pyridine-lipids prior to their combination. by the formation of a tertiary amine. 
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Figure 20 Synthesis of the final product from compound 40. 
 
 As shown in Figure 21, compound 33 underwent ester hydrolysis and was then coupled 
with long chain amine to form alcohol 42, after which compound 43 was produced by 
refluxing with thionyl chloride. After treating 43 with sodium azide and reducing under 
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hydrogen, compound 44 was formed. 
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N
OHN
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Figure 21 Synthesis of long chained amide 44. 
 
 The final step in the synthesis of 41 is a trimerization through reaction of amine 44 with 
2 equivalents of halide 43. However, this step was unsuccessful under the conditions that 
were explored. 
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Figure 22 Attempted final step in the conversion of 44 to 41. 
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2.5 Future work 
Synthetic efforts brought us to within one step of proposed zinc trigger 41, but the final 
coupling reaction was not successful. Completion of the synthesis of 41will enable liposome 
release studies as previously described. Titrations using ZnCl2 solutions will be performed to 
determine the concentrations of Zn2+ required to release the contents and see if this is 
relevant to the abundances found in the human body. The titration of competing ions will 
also be performed, especially Na+ and K+, which are abundant in blood vessels. Buffers 
mimicking the blood pH and temperature should be used to examine the stability of the 
liposomes under these conditions. Liposomes formed need to circulate long enough in blood 
vessel to achieve the delivery goal, due to the low percentage of free Zinc inside the human 
body.  
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Chapter 3: Experimental 
1 D-2,3-O - (D- 1’,7’,7’-Trimethy1[2.2.1 ]bicyclohept-2’-ylidene) -myo – inositol (2): 
OH
HO OH
OH
HO OH
1
O
O
OH
OH
HO OH
2
OMe
OMe
1
2
3
4
5
6
1
23
4
5 6
 This compound was synthesized as previously described by Bruzik and co-workers.31In a 
100mL round bottomed flask, 3.6g (23.6mmol) of D-Camphor was mixed with 28mL 
(256mmol) of trimethyl orthoformatein 11mL of dry methanol. Then, two drops of 
concentrated sulfuric acid were added to the flask and the mixture was allowed to stir for 2 
days at rt. Afterwards, the resulting precipitate was filtered off with chloroform, and the 
solvent was then evaporated to dryness to obtain a pure yellow oil. Next, 1.5g (8.3mmol) of 
myo-inositol was dissolved in 16mL of DMSO along with the crude oil under nitrogen. Two 
drop of concentrated sulfuric acid were then added. The mixture was then allowed to stir at 
800C for 5h, during which the white inositol solid dissolved. The reaction was monitored by 
TLC (10:1 chloroform: MeOH). Next, two drops of NEt3was added to quench the reaction 
after which the solvent was evaporated, producing an orange sticky gel. To this was added 
28.5mL chloroform, 10.5mL MeOH and 0.8mL water plus 100mg (581mmol) TsOH. The 
mixture was then allowed to stir overnight at rt, during a white precipitate formed, which 
was filtered off and then washed with chloroform. The organic layers were then combined 
and the solvent was removed by rotary evaporation. The resulting crude was added to a 
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500mL round-bottomed flask along with 400mL of methanol and 4mL of NEt3. This solution 
was heat to 75-800C for 30 min to dissolve the majority of solids and then filtered while hot 
to obtain a clear solution. Half of the solution was evaporated and then the solution was 
placed in the fridge. After 2 days crystals formed, which were isolated through filtration to 
obtain clear crystals. The crystals yielded an optical rotation of [α]D= +30.10(c=1.9) in 
pyridine. The sample was recrystalized again using the same 1% NEt3/MeOH solvent system, 
after which the optical rotation reached [α]D=+44.60 in pyridine with c=1.9. This resulted in 
278mg  (0.89mmol) of product, 11% yield. All the data matched the literature.31 
NMR (500MHz) (CD3OD): δ 4.27 ppm (t, 1H, J = 5.5 Hz), 3.76 (t, 1H,J = 7.2 Hz), 3.67 (t, 1H, ), 
3.58 (t, 1H, J = 9.6 Hz), 3.48 (t, 1H,J = 9.3 Hz), 3.20 (m, 2H), 1.72 (m, 2H), 1.50 (d, 1H, , J = 
10.1Hz), 1.30 (m, 2H), 1.20 (m, 2H), 1.07 (s, 3H), 0.87 (s, 3H), 0.83(s, 3H). 
 
1D-1-O-( tert-Butyldipbenylsiyl)-2,3-0-(D-1’,7’,7’-trimethy1[2.2.1]bicyclobept-2’-ylidene)-my
o-inositol (3): 
O
O
OH
OH
HO OH
2
O
O
OTBDPS
OH
HO OH
3
TBDPSCl
Imidazole
1
2
3
4
5
6
 This compound was synthesized as previously described by Bruzik and co-workers.31278mg 
(0.88mmol) of compound2was added to a 50mL round-bottomed flask along with 86mg 
(1.26mmol) of imidazole under nitrogen. Next, 2.8mL of dry pyridine was added and the 
reaction was cooled to -100C in a NaCl salt bath. To this solution was slowly dropped in 
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0.23mL (0.88mmol) of TBDPSCl. After stirring at rt overnight, the solvent was removed by 
rotary evaporatation. Next, 10mL of water was added and the mixture was extracted with 
3x10mL of EtOAc. The combined organic layers were then dried with sodium sulfate and 
column with 15:1 chloroform/MeOH was used to obtain 367mg (0.66mmol)of clear glassy 
solid, for a yield 75%, Rf=0.42. The characterizations matched the literature31. 
NMR (300MHz) (CDCl3): benzene 10H 7.72 (d, J=3.7Hz), 7.57(t, J=3.6Hz), 7.42-7.30 (m), 
7.30-7.24 (m), 3.91(t, 1H, J = 3.7Hz), 3.50(t, 1H, , J = 3.5Hz), 3.20(m, 1H), 3.0 (t, 1H, , J = 3.1 
Hz), 2.24 (s, 2H), 1.26-1.00 (multiple S, 9H).  1D-4, 5-O-bisbenzoyl-1-O-(tert-butyldiphenylsilyl)-2, 3-O-(D-1’, 7’, 
7’-trimethyl[2.2.1]bicyclohept-2’-ylidene)myo-inositol (4): 
O
O
OTBDPS
OH
HO OH
3
BzCl
Pyridiene
O
O
OTBDPS
OBz
BzO OH
4  This compound was synthesized as previously described by Bruzik and co-workers.31Triol 3 
(100mg,0.18mmol) was dissolved in 1mL of dry pyridine and 0.2mL dry dichloromethane in 
a 25mL round-bottomed flask. This was cooled to -400Cand 0.05mL (0.43mmol) of benzoyl 
chloride was slowly dropped into the reaction. The mixture was allowed to stir until the 
temperature reached room temperature. The reaction was then quenched with 10mL wet 
EtOAc and the solvent was removed by rotary evaporation. Afterwards, the product was 
purified by column chromatography (5:1 Hexane/Acetone) to afford 97mg of a glassy solid 
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(Rf=0.34, 3:1 hexane/acetone) in70% yield. The characterizations matched the literature31. 
NMR (500MHz) (CDCl3):δ7.50-7.95 (m, 7H), 7.00-7.50 (m, 17H), 5.50(t, 1H J = 8.5Hz), 5.32(t, 
1H, J = 6.7Hz), 4.50(t, 1H, J = 7.8Hz), 4.00(m, 3H), 1.26-1.07(m, 13H), 1.00-1.07 (s, s, s, s, 
15H), 0.89-1.00 (m, 7H). 
 
1D-4, 5-bisbenoyl-1-O-(tert-butyldiphenylsilyl)-myo-inositol (5): 
O
O
OTBDPS
OBz
BzO OH
4
TFA
CHCl3
HO
HO
OTBDPS
OBz
BzO OH
5  This compound was synthesized as previously described by Bruzik and co-workers.3197mg 
(0.13mmol) of alcohol 4wasdissolved in 9.7mL of chloroform in a 50mL round-bottomed 
flask. To this was added 1mL of a 5% solution of TFA in water and the reaction was allowed 
to stir overnight. The solvent was then removed by rotary evaporation the resulting crude 
was purified by column chromatography with 3:1 hexane/acetone as eluant, Rf=0.32. This 
yielded 73mg (0.12mmol) of triol 5(91%). The characterizations matched the literature31. 
NMR (300MHz)(CDCl3):δ 7.95-7.90(m, 4H), 7.74-7.71(m, 4H), 7.0-7.5 (m, 13H), 5.70(t, 1H, J 
= 9.8 Hz), 5.28(t, 1H, J = 9.6 Hz), 4.32(t, 1H, J = 2.6 Hz), 4.00(t, 1H, J = 2.5 Hz), 3.71(d, 1H, J = 
3.2 Hz), 3.59(d, 1H, J = 3.5 Hz), 2.5(broad s, 4H), 1.12(s, 9H).       
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4, 5-O-bisbenzyl-2, 3, 6-O-tri(benzyloxymethyl)-1-O-(tert-butyldiphenylsily)-D-myo-inositol: 
HO
HO
OTBDPS
OBz
BzO OH
5
BOMO
OBOM
OTBDPS
OBz
BzO OBOM
BOMCl
 This compound was synthesized as previously described by Best and co-workers35. Triol 5 
(100mg, 0.16mmol) was dissolved in 4mL of 1,2-dichloroethane in a 50mL round-bottomed 
flask. To this was added 0.2mL (1mmol) of DIPEA and 0.2mL (1.2mmol) of BOMCl, after 
which the reaction mixture was refluxed for 8h. Another portion of DIPEA and BOMCl was 
then added, followed by refluxing overnight. Wash the solution with 10mL water and dry the 
solvent with anhydrous sodium sulfate. The product was purified by column 
chromatography through gradient elution with 8:1 hexane/acetone5:1 hexane/acetone 
2:1 hexane/acetone to obtain 135mg (0.14mmol) of the product as a yellow oil (yield = 86%. 
Rf=0.45 (hexane:acetone=3:1)). The characterizations matched the literature value35. 
NMR (300MHz) (CDCl3):δ 7.92-7.74 (m, 8H), 7.40-7.16 (m, 28H), 5.93(t, 1H, J = 12Hz), 5.51(t, 
1H, J = 12Hz), 5.06(d, 1H, J = 6 Hz), 4.3 (m, 4H), 4.5(m, 3H), 4.0-4.32(m, 9H), 3.92(d, 1H, 
J=60Hz), 3.69 (d, 1H, J=12Hz), 3.59 (s, 1H), 1.0 (s, 9H). 
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2, 3, 6-O-tri(benzyloxymethyl)-1-O-(tert-butyldiphenylsily)-myo-inositol (6): 
BOMO
BOMO
OTBDPS
OBz
BzO OBOM
 
MeONa, MeOH
BOMO
OBOM
OTBDPS
OH
HO OBOM
6  This compound was synthesized as previously described by Best and co-workers35. 135mg 
(0.14mmol)of starting material was added into a 50mL of round-bottomed flask with an 
excess amount of 50mg (0.92mmol) MeONa in 10mL methanol. The reaction as then allowed 
to stir overnight. Quenched with 5mL water, extract with 3x10mL chloroform and dried with 
anhydrous sodium sulfate. Columned to gain 57mg (0.07mmol) of yellow oil, yield 54%, via 
hexane/acetone=3:1, Rf=0.39. The characterizations matched the literature35. 
NMR (300MHz) (CDCl3):δ7.71-7.39(m, 4H), 7.37-7.20(m, 21H), 5.30-4.67 (m, 13H), 4.55(t, 
2H, J=3Hz), 3.80 (s, 2H), 3.40(d, 1H,J = 6 Hz), 3.20(s, 1H), 2.8(s, 1H), 1.0(s, 9H). 
 
2, 3, 6-O-tri(benzyloxymethyl)-1-O-(tert-butyldiphenylsily)-D-myo-inositol4,5-bis(dibenzyl 
phosphate) (7): 
BOMO
OBOM
OTBDPS
OH
HO OBOM
6
1. 1H-tetrazole, CH2Cl2, MeCN
2. m-CPBA
P
N
BnO OBn BOMO OTBDPS
O
O OBOM
OBOM
P
P
O
O
BnO
BnO
BnO OBn
7  This compound was synthesized as previously described by Best and co-workers35. 57mg 
(0.07mmol) of compound 6 was added into 2mL of dry DCM in a 25mL round-bottomed 
flask under argon. Next, 0.2mL of phosphoramidite reagent and 0.1mL of tetrazole solution 
(0.1mM) were added and the reaction was allowed to stir at rt for 4h. After that, another 
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0.2mL of phosphoramidite coupling reagent and 0.1mL tetrazole were added to the solution 
and it was stirred for 2h. Then, the reaction was dropped to 0oC in an ice bath and 50mg 
(0.3mmol) of m-CPBA was added. The reaction was allowed to stir for 2h, and then quenched 
with saturated sodium bicarbonate solution and extracted with 3x10mL chloroform. The 
combined organic layers were dried with sodium sulfate, filtered and the solvent was 
removed by rotary evaporation. Column chromatography with 5:1 hexane/acetone3:1 
hexane/acetone afforded 96%yield of product 7 as 91mg (0.06mmol) pure yellow oil. The 
characterizations matched the literature value35.  2, 3, 6-O-tri(benzyloxymethyl)-D-myo-inositol 4,5-bis(dibenzyl phosphate)) (8): 
BOMO OTBDPS
O
O OBOM
OBOM
P
P
O
O
BnO
BnO
BnO OBn
7
TBAF
BOMO OH
O
O OBOM
OBOM
P
P
O
O
BnO
BnO
BnO OBn
8
Chloroform  This compound was synthesized as previously described by Best and co-workers35. 86mg 
(0.066mmol) of starting material 7 was added to a 25mL of round-bottomed flask along with 
an excess amount of60mg (0.23mmol) TBAF in 4mL chloroform. The reaction mixture was 
allowed to stir overnight. Next, the reaction crude was washed with 2x5mL water. The 
organic layer was then dried with sodium sulfate, filtered and the solvent removed by rotary 
evaporation. Column chromatography with 5:1 hexane/acetone provided35mg (0.032mmol) 
of 8 as a clear solid (yield 50%. Rf= 0.36 in 3:1 hexane/acetone). The characterizations 
matched the literature35. 
NMR (300MHz) (CDCl3):δ1HNMR: 7.59(s, 1H), 7.37-7.21(m, 34H), 5.60(s, 2H), 5.30(s, 18H), 
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5.14-4.75(m, 10H), 4.59(d, 1H, J=6Hz), 4.48(d, 1H, J=9Hz), 4.45(d, 1H, J=6Hz), 4.43-4.41 (m, 
4H), 4.20(broad s, 1H), 4.16(s, 1H), 3.75(t, 1H, J=6Hz), 3.58(d, 1H, J=6Hz), 3.43-4.40 (three s, 
10H), 31PNMR: -1.28ppm, -1.69ppm.     4,5-O-bisbenzyl-2,3,6-O-tris(methoxymethylene)-1-O-(tert-butyldiphenylsily)D-myo-inositol: 
MOMO
OMOM
OTBDPS
OBz
BzO OMOM  This compound was synthesized as previously described by Bruzik and co-workers.3173mg 
of triol 5 was placed under nitrogen in 25mLround-bottomed flask in 1mL of dry DMF. 
Afterwards, 0.1mL of DIPEA was added, followed by 0.03mL of MOMCl. A white cloudy 
solution formed and the reaction mixture was allowed to stir in a 650C hot bath for 
24h.Column chromatography with 8:1 hexane/acetone eluant afforded73mg of clear oil，
Rf=0.36, 83% yield 83%. The characterizations matched the literature31. 
NMR (300MHz) (CDCl3):δ 7.96(d, 2H, J=6Hz), 7.87(d,2H, J=6Hz), 7.78-7.74(m, 3H), 
7.46-7.25(m, 10H), 5.82(t, 1H, J = 6Hz), 5.43(t, 1H, J = 6Hz), 4.95 (d, 1H, J = 6Hz), 4.69(d, 1H, 
J=6Hz), 4.59(d, 1H, J=6Hz), 4.56(d, 1H, J=3Hz), 4.36(t, 1H, J=4.5Hz), 4.28(d, 1H, J=6Hz), 
4.15-4.05(m, 1H), 4.02(d, 1H, J=6Hz), 3.55 (d, 1H, J=6Hz), 3.44(s, 1H), 3.34(s, 2H), 2.98-2.96 
(s, s, 5H), 1.12(s, 9H).       
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2,3,6-O-tris(methoxymethylene)-1-O-(tert-butyldiphenylsily)-D-myo-inositol (19): 
 
This compound was synthesized as previously described by Bruzik and co-workers.3173mg 
(0.12mmol) of starting material was stirred overnight in 2mL MeOH and along with an 
excess amount of 80mg (1.5mmol) of MeONa. The next day, 10mL of water was added and 
the crude was extracted with 3x10mL of dichloromethane. The solution was dried with 
anhydrous sodium sulfate and column chromatography with 5:12:1 hexane/acetone 
provided liquid diol19(37mg (0.07mmol),Rf=0.34,3:1 hexane/acetone). The 
characterizations matched the literature31. 
NMR (300MHz)(CDCl3):δ 7.69(t,, 4H, J=4.5Hz), 7.43-7.26(m, 6H), 4.83(d, 1H, J=3Hz), 4.69(s, 
1H), 4.64(d, 1H, J=3Hz), 4.59(d, 1H, J=6Hz), 4.47(s, 2H), 4.16(d, 1H, J=3Hz), 3.88(s, 1H, 
J=6Hz), 3.79(s, 1H), 3.72(s, 2H), 3,37, 3,34, 3.26(s, s, s, 9H), 3.13(t, 1H, J=4.5Hz), 1.06 (s, 9H). 
 
2,3,6-O-tris(methoxymethylene)-1-O-(tert-butyldiphenylsily)-D-myo-inositol-4,5-bis(dibenz
yl phosphate) (20): 
MOMO
OMOM
OTBDPS
OH
HO OMOM
1. 1H-tetrazole, CH2Cl2, MeCN
2. m-CPBA
P
N
BnO OBn
MOMO OTBDPS
O
O OMOM
OMOM
P
P
O
O
BnO
BnO
BnO OBn
19
20  This compound was synthesized as previously described by Bruzik and co-workers.3137mg 
MOMO
OMOM
OTBDPS
OH
HO OMOM
MeONa/MeOH
19
MOMO
OMOM
OTBDPS
OBz
BzO OMOM
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(0.07mmol) of starting material 19was dissolved in 5mL of dry dichloromethane in a 25mL 
round-bottomed flask under argon. 47mg (0.14mmol) of phosphoramidite coupling reagent 
in 2mL of dry dichloromethane was then added. Afterwards, 0.1mL tetrazole solution 
(0.1mM). The reaction was then allowed to stir for 2h. Next, another 47mg (0.14mmol) of 
coupling reagent with 0.1mL of tetrazole solution was added. The reaction was allowed to 
stir for another 4h.After that, the reaction was placed in an ice bath and 20mg m-CBPA was 
added. The reaction was then worked up with saturated sodium bicarbonate and extracted 
with 3x10mL dichloromethane. Column chromatography with 3:1 hexane/acetone 
afforded69mg (0.066mmol) clear oil, 95% yield Rf=0.52. The characterizations matched the 
literature31. 
 
2,3,6-O-tris(methoxymethylene) -D-myo-inositol-4,5-bis(dibenzyl phosphate) (21): 
MOMO OTBDPS
O
O OMOM
OMOM
P
P
O
O
BnO
BnO
BnO OBn
MOMO OH
O
O OMOM
OMOM
P
P
O
O
BnO
BnO
BnO OBn
TBAF
20 21  This compound was synthesized as previously described by Bruzik and co-workers.3169mg 
(0.06mmol)of starting material 20 was dissolved in 5mL chloroform and50mg (0.9mmol) 
TBAF was added. The reaction was allowed to stir for 4h and then washed with 2x5mL water. 
The organic layer was dried with anhydrous sodium sulfate and the solvent was removed by 
rotary evaporation. Column chromatography with 3:1 hexane/acetone afforded45mg 
(0.05mmol) of clear oil (yield 80%, Rf=0.47). The characterizations matched the literature31. 
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(S)-4-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane (10): 
O O
HO
9
O O
PMBO
10
PMBCl
NaH, DMF
 According to the literature.34100mg (0.76mmol) of alcohol 9 was dissolved in 2.0mL of dry 
DMF under argon and 200mg (8.3mmol) of NaH was added. After stirring for1h, 0.13mL 
(0.8mmol) of PMBCl was injected into the flask and the solution was stirred overnight. 5mL 
water was then added to quench the reaction. The product was extracted with 3x10mL 
EtOAc and the resulting organic solution was dried with anhydrous sodium sulfate, filtered 
and the solvent removed by rotary evaporation. Purification with column chromatography 
used a gradient of pure hexane to 15 % EtOAc/Hexane to afford 5 as an oil, (Rf =0.53 in 15% 
EtOAc). This produced 161mg (0.64mmol, 85% yield) of compound. The characterizations 
matched the literature34. 
NMR (300MHz) (CDCl3):δ 7.24(d, 2H, J=6Hz), 6.86(d, 2H, J=6Hz), 4.48(q, 2H, J=6Hz), 4.26(t, 
1H, J=3Hz), 4.02(t, 1H, J=6Hz), 3.78(s, 3H), 3.71(t, 1H, J=4,5), 3.53-3.44 (m, 2H), 1.41(s, 3H), 
1.24(s, 3H). 
 
(R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol (11): 
O O
PMBO
HO OH
PMBO
MeOH, TsOH
or AcOH
1110  According to the literature.34110mg (0.44mmol)of 10wasinjected inside a 100mL 
round-bottomed flask. 10mL of 15% HCl in MeOH/Chloroform (1:10) was added and the 
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mixture was heated under 800C and stirred overnight. The solvent was removed by rotary 
evaporation and the crude was purified by column chromatography with gradient elution 
with Hexane50% EtOAc/Hexanes to obtain product 11 as a white solid (83mg, 0.39mmol, 
89%). The characterizations matched the literature34. 
NMR (300MHz) (MeOH-D4):δ 7.20(d, 2H, J=6Hz), 6.82(d, 2H, J=6Hz), 3.71(s, 2H), 4.40(s, 3H), 
3.42-3.39(m, 4H). 
 
(S)-1-((4-methoxybenzyl)oxy)propane-1,2-diyl bis(octadecanoate-d35): 
O O
PMBO
O O
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D3C
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D3C  In a small vile 20mg (0.09mmol) compound 11 was been pre-dried. Weight 70mg (0.22mmol) 
stearic-d35 acid and transfer them into the vile. Add 106mg (0.5mmol) DCC and 30mg 
(0.25mmol) DMAP into the vile. Add in 2mL dry dichloromethane and the mixture was 
stirred under rt for 12h. Filter the mixture and evaporate the solution to get white solid. 
Column with gradient of pure Hexanes to 5% EtOAc/Hexanes (Rf=0.58) to gain 57mg 
(0.07mmol), yield 77.8%. 
NMR (300MHz) (CDCl3): 1HNMR δ7.16(d, 2H, J=6Hz), 6.80(d, 2H, J=6Hz), 5.17-5.13(m, 1H), 
4.39(q, 2H, J=6Hz), 4.25(d, 1H, J=3Hz), 4.12-4.08(m, 1H), 3.79(s, 3H), 3.49(s, 2H); 13CNMR δ 
57 
 
159.24, 129.71, 129.22, 113.74, 77.98, 69.93, 67.85, 62.21, 55.18. 
(M+1)(TOF)=746.1739 (M+1)(calculation)=746.173651. 
 
(S)-3-hydroxypropane-1,2-diyl bis(octadecanoate-d35): 
O O
HO
O O
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D3C
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D3C  In 25mL round bottom flask 20mg (0.03mmol) starting materials was dissolved in 2mL 
dichloromethane and 0.5mL water. 7mg (0.03mmol) DDQ was added and the mixture was 
stirred under rt for 2h. Another 7mg DDQ was added and the mixture was stirred for excess 
3h. Quench the reaction with 5mL saturated sodium bicarbonate solution. Extract the 
product using 3x10mL dichloromethane. Wash with 3x5mL water to reduce the dark yellow 
solution to faint yellow color. Dry the organic with anhydrous sodium sulfate. Column with 
gradient of 5% EtOAc/Hexanes to 15% EtOAc/Hexanes (Rf=0.39), to gain white solid of 
17mg (0.025mmol). Yield 83%. 
NMR (300MHz) (CDCl3): 1HNMR δ 5.38(t, 1H, J=3Hz), 4.33-4.21(m, 2H), 3.73(m, 2H); 
13CNMR δ161.62, 72.10, 61.97, 61.59, 28.37, 27.44. 
(M+1)(TOF)=626.0255 (M+1)(calculation)=626.025131. 
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(R)-3((bis(benzyloxy)phosphoryl)oxy)propane-1,2-diyl bis(octadecanoate-d35): 
O O
O
O O
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D3C
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D2C
CD2
D3C
P
O
O
O
 In pre-dried 10mL round bottom flask, 30mg (0.05mmol) of starting material was dissolved 
in 2mL dry dichloromethane and the system was protected by argon. 35mg (0.1mmol) 
dibenzyl diisopropylphosphoramidite was injected with 2mL of dry dichloromethane. After 
injecting 0.1mL 0.1mM 1H-tetrazole solution, the mixture was stirred for 10h under rt. Cool 
the flask with ice bath, add 20mg (0.12mmol) m-CPBA and stir the mixture for 3h. Quench 
the reaction with 5mL saturated sodium bicarbonate. Extract the solution with 3x10mL 
dichloromethane. Dry with anhydrous sodium sulfate. Column with gradient of 15% 
EtOAc/Hexanes (Rf=0.62) to gain 39mg (0.041mmol) white solid. Yield 82%. 
NMR (300MHz) (CDCl3): 1HNMR δ7.35-7.31(m, 10H), 5.18-5.14(m, 1H), 5.04-4.97(s, s, 4H), 
4.25(d, 1H, J=12Hz), 4.12-4.06(m, 3H), 3.52-3.45(m, 1H); 31PNMR δ -1.04. 
(M+1)(TOF)=956.0766 (M+1)(calculation)=956.076155. 
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(2S)-3-(((benzyloxy)(diisopropylamino)phosphaneyl)oxy)-2-((tert-butoxycarbonyl)amino)p
ropanoic (tert-butyl carbonic) anhydride (24): 
HO
NHBoc
O
OBoc
1. 1H-tetrazole    
CH2Cl2
P
N
N
BnO
16
2. quench with NaHCO3
O
NHBoc
O
OBoc
P OBn
N
24  20mg (0.065mmol) of16 was added to a small sealed vile along with 2mL of dry 
dichloromethane, which was then degasssed. Next, 23mg (0.068mmol) of phosphoramidate 
reagent was added was dissolved in 5mLdichloromethane and added to the reaction along 
with 1mL 1H-tetrazole solution (0.1mM). The reaction was allowed to stir for 4h and then 
quench with saturated sodium bicarbonate solution. The crude was then extracted with 
3x10mL dichloromethane, dried with anhydrous sodium sulfate and the solvent removed by 
rotary evaporation. Next, column with 20% EtOAc/Hexanes with 1% gradient of 
triethylamine provided the product as a clear solid (21mg, 0.04mmol, 60% yield. Rf=0.38 (15% 
EtOAc/Hexanes)). 
NMR (500mHz) (CDCl3): 1HNMR: δ7.29-7.18 (m, 5H), 5.35(dd, 1H, J1=5Hz, J2=10Hz), 
4.96-4.55(m, 2H), 4.23(d, 1H, J=15Hz), 4.01-3.94(m, 1H), 3.92-3.73(m, 1H, m), 3.55-3.39(m, 
2H), 1.69(s,2H), 1.39, 1.37, 1.36(s, s, s,14H), 1.35-1.08(m, 13H). 31PNMR: 148.57ppm, 
148.08ppm, 147.67ppm.  
(M+1)(TOF)=529.5830 (M+1)(cal.)=529.582792 
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Diethyl pyridine-2,4-dicarboxylate (32): 
N COOH
COOH
N COOCH2CH3
COOCH2CH3
Dry ethanol
TsOH, reflux
28 32  This compound was synthesized as previously described in the literature.82200mg 
(1.20mmol)of compound 28 was dissolved in 10mL absolute ethanol and 400mg 
(2.33mmol)of TsOH was added. After refluxing the solution for 24h, the solvent was 
evaporated and the remaining solid was neutralized with saturated sodium bicarbonate. The 
solution was extracted with 3x10mL chloroform, and the combined organic layers were 
dried with sodium sulfate, filtered, and the solvent was evaporated. Column chromatography 
with 15% EtOAc/hexanes afforded 202mg (0.91mmol) product (76% yield, Rf=0.6). The 
characterizations matched the literature82. 
NMR (500MHz) (CDCl3): δ 8.93(d, 1H, J=5Hz), 8.65(s, 1H), 4.53(q, 2H, J=7.5Hz), 4.47(q, 2H, 
J=8Hz), 1.48(t, 3H, J=7.5Hz), 1.27, 1.26, 1.25(t, 3H, J=5Hz). 
 
Ethyl 2-(hydroxymethyl)isonicotinate (33): 
N COOCH2CH3
COOCH2CH3
N
COOCH2CH3
OH
CaCl2, NaBH4
Dry EtOH, -10-00C
32 33  This compound was synthesized as previously described in the literature.82200mg 
(0.89mmol) of compound 32 was dissolved in 10mL of degassed ethanol solution. 20mg 
(0.53mmol) of sodium borohydride was added along with 100mg (0.90mmol) of dry calcium 
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chloride dissolved in 5mL ethanol. The mixture was stirred in an ice bath for 5h and then 
quenched with a drop of sulfuric acid. The solution was filtered and washed with 3x10mL 
ethanol. The solvent was then evaporated column chromatography with 15% 
chloroform/methanolprovided134mg (0.74mmol) of 33 as a white solid ( 83% yield, 
Rf=0.51). The characterizations matched the literature82. 
NMR (500MHz) (MeOH-D4): δ 8.93(d, 1H, J=10Hz), 8.46(s, 1H), 5.09(s, 2H), 4.47(q, 2H, 
J=11.5Hz), 1.42(t, 3H, J=12.5Hz). 
 
Ethyl 2-(chloromethyl)isonicotinate (34): 
N
O O
Cl
34  50mg (0.28mmol) of compound 33 was added into 5mL of thionyl chloride in a 50mL 
round-bottomed flask and heated to reflux for 12h. The solvent was removed by rotary 
evaporation, add 10mL dichloromethane was added and the resulting solution was washed 
with 2x10mL water. The organic solution was then dried with anhydrous sodium sulfate. 
Column chromatography with 25% EtOAc/hexanes afforded47mg (0.24mmol) of yellow film, 
86% yield, Rf=0.48. 
NMR (300MHz) (CDCl3): 1HNMR δ 8.65(d, 1H, J=3Hz), 7.94(s, 1H), 7.72(d, 1H, J=3Hz), 4.65(s, 
2H), 4.35(q, 2H, J=5.1Hz), 1.34(t, 3H, J=4.5Hz). 13CNMR δ 165.04, 164.54, 157.55, 150.09, 
138.79, 138.41, 122.17, 121.96, 61.85, 52.69, 48.21, 46.18, 14.07 
(M+1)(TOF)= 200.0408; (M+3)(TOF)=202.0410 (M+1)(cal.)=200.04728 
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Ethyl 2-(bromomethyl)isonicotinate (35): 
N
O O
Br
35  50mg (0.28mmol) of 33 was added to a solution of 3mL of PBr3in 5mL of dry 
dichloromethane inside a 50mL round-bottomed flask. The solution was allowed to stir for 
8h, and then quenched with methanol and washed with 3x10mL water. The organic layer 
was dried with anhydrous sodium sulfate and then column chromatography with 25% 
EtOAc/hexanes afforded 63mg (0.26mmol) of clear solid product (96% yield and Rf=0.43). 
The product became purple after 3 days. 
NMR (500MHz) (CDCl3): δ 8.74 (d, 1H, J=5Hz), 8.01(s, 1H), 7.80(d, 1H, J=5Hz), 4.62(s, 2H), 
4.43(q, 2H, J=6.5Hz), 1.43(t, 3H, J=7.5Hz). 
(M+1)(TOF)=243.9925; (M+3)(TOF)=245.9907 (M+1)(cal.)=243.99677   Ethyl 2-(azidomethyl)isonicotinate (37): 
N
O O
N3
37  20mg (0.08mmol) of compound 35 was refluxed along with 50mg (0.80mmol) of sodium 
azide and a tiny piece of NaI in 5mL of MeCN solution. The product was filtered and column 
chromatography with 15% EtOAc/hexanes yielded a yellow film of 18mg (0.078mmol) of 37, 
98% yield. 
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NMR (300MHz) (CDCl3): δ 8.76 (d, 1H, J=3Hz), 7.90(s, 1H), 7.81(s, 1H), 4.57(s, 2H), 4.43(q, 
2H, J=3Hz), 1.43(t, 3H, J=3Hz). 
(M+1)(TOF)=207.0869 (M+1)(Cal.)=207.087652 
 
Ethyl 2-(aminomethyl)isonicotinate (38): 
N
O O
NH2
38  18 mg (0.09mmol)of compound 37 was reduced with pd/C (5-10%) in EtOAc.After removing 
the catalyst by filtration, column chromatography with pure chloroform -> 5% 
chloroform/methanol ->25% chloroform/methanol resulted in 9mg (0.05mmol)of amine 38, 
64% yield, Rf=0.30. 
NMR (300MHz) (MeOH-D4): δ 8.70(d, 1H, J=9Hz), 7.90(s, 1H), 7.68(s, 1H), 4.37(q, 2H, 
J=3.9Hz), 4.00(broad S, 2H), 3.28(s, 2H), 1.37(t, 3H, J=4.5Hz). 
(M+1)(TOF)=181.0896 (M+1)(cal.)=181.09715. 
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triethyl 2,2',2''-(nitrilotris(methylene))triisonicotinate (39): 
NN
N
N
O
O
O
O
O
O
N
O O
NH2
38
                  
34 
        
35
Li2CO3     Y 80% 
     
Y 92%
Na2CO3   Y 43% 
     
Y 54%
K2CO3      N 
             
Y 24% 
Cs2CO3   N 
             
N
CH2Cl2
39  10mg (0.06mmol) of compound 38 was reacted with an excess amount of 25mg (0.13mmol) 
of compound 34 or 35mg (0.14mmol) compound 35 to achieve the above yield of 24mg 
(0.05mmol)(80%) and 28mg (0.06mmol)(92%), respectively. The reaction with chlorinated 
compound 34 was slow in rate and lower in yield. In order to accelerate the reaction, tiny 
pieces of NaI were added. Column chromatography was performed with gradient elution 
from chloroform to 5% chloroform/MeOH, Rf=0.71 (5% chloroform/MeOH). 
NMR (500MHz) (CDCl3): 1HNMR δ 8.68(d, 1H, J=5Hz), 8.08(s, 1H), 7.70(d, 1H, J=5Hz), 4.41(q, 
2H, J=6.5Hz), 4.03(s, 2H), 1.41(t, 3H, J=5Hz).13CNMR δ 165.19, 160.20, 149.86, 138.24, 
122.37, 61.89, 60.06.  
(M+1)(TOF)=507.2241 (M+1)(cal.)=507.22381 
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N-dodecyl-2-(hydroxymethyl)isonicotinamide (42): 
N
OHN
HO
 100mg (0.6mmol) of compound 33 was refluxed in 2M NaOH solution with equal volume of 
water. After 1 day, the solution was acidified with 0.1M HCl (test with pH paper) and the 
solvent was removed by rotary evaporation. Pour 10mL of boiling n-butanol to dissolve the 
organic compound. The salt was removed by filtration, and the solvent was evaporated. Next, 
150mg (0.76mmol) of EDCI and 150 mg (0.8mmol) of dodecan-1-amine were added. The 
reaction was allowed to stir for 12h and column chromatography with 50% EtOAc/hexanes 
(Rf=0.48) yielded162mg (0.51mmol) product (65%). 
NMR (500MHz) (CDCl3): δ 8.69(d, 1H, J=5Hz), 7.77(s, 1H), 7.54(d, 1H, J=10Hz), 6.19(broad s, 
1H), 4.73(S, 2H), 3.47(t, 2H, J=10Hz), 1.64(m, 9H), 1.26(m, 20H), 0.87(t, 3H, J=10Hz). 
(M+1)(TOF)=321.2523 (M+1)(cal.)=25365 
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2-(chloromethyl)-N-dodecylisonicotinamide (43): 
N
OHN
Cl
43  150mg (0.47mmol) of compound 42 was added into 5mL thionyl chloride to react. The 
mixture was refluxed at 800C for 12h.Quench the reaction with 5mL water after evaporating 
the thionyl chloride. Extract with 3x10mL chloroform. Wash again with 2x5mL water than 
5mL brine. Dry with anhydrous sodium sulfate and column to get yellow solid. Rf=0.5 (25% 
EtOAc/Hexanes). Yield 110mg (0.33mmol), 70%. 
NMR (500MHz) (CDCl3):1HNMR δ 8.68(d, 1H, J=10Hz), 7.93(s, 1H), 7.55(d, 1H, J=5Hz), 
8.29(broad, s, 1H), 3.57-3.43(m, 2H), 1.68-1.58(m, 3H), 1.06(m, 20H), 0.90, 0.88, 0.85(t, 3H, 
J=12.5Hz). 13CNMR δ 165.17, 159.08, 150.20, 142.23, 120.27, 120.00, 46.34, 40.38, 31.92, 
29.64, 29.59, 29.53, 29.35, 29.29, 26.98, 22.69, 14.12. 
(M+1)(TOF)=339.2172; (M+3)(TOF)=341.2166 (M+1)(cal.)=339.21976     
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